Skip to main content

Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.

Publication ,  Journal Article
Welsh, RC; Dehghani, P; Lopes, R; Wojdyla, DM; Aronson, R; Granger, CB; Windecker, S; Vora, AN; Vinereanu, D; Halvorsen, S; Parkhomenko, A ...
Published in: Open Heart
February 2022

OBJECTIVE: Managing antithrombotic therapy in patients with atrial fibrillation (AF) and an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) is challenging and can be affected by prior oral anticoagulant (OAC) treatment. We examined the relationship between prior OAC use and outcomes in the AUGUSTUS trial. METHODS: This prespecified secondary analysis is from AUGUSTUS, an open-label, 2-by-2 factorial, RCT to evaluate the safety of apixaban versus vitamin K antagonist (VKA) and aspirin versus placebo in patients with AF and ACS and/or PCI. The primary endpoint, major or clinically relevant non-major bleeding and clinical outcomes were compared in patients receiving (n=2262) or not receiving (n=2352) an OAC prior to enrolment. RESULTS: Patients with prior OAC use had more comorbidities, higher CHA2DS2-VASC and HAS-BLED scores, and were more likely enrolled following elective PCI. There was no difference in major or clinically relevant non-major bleeding with or without prior OAC (30 days: 5.1% vs 5.9% (adjusted HR (aHR) 0.82, 95% CI 0.63 to 1.06); 180 days: 13.5% vs 13.5% (aHR 0.98, 95% CI 0.83 to 1.16)). Patients with prior OAC use had a lower risk of death or ischaemic events (30 days: 1.7% vs 2.8% (aHR 0.61, 95% CI 0.41 to 0.92); 180 days: 5.4% vs 7.6% (aHR 0.70, 95% CI 0.55 to 0.88)). No interactions between randomised treatment (apixaban vs VKA, aspirin vs placebo) and prior OAC status were observed for outcomes, apart from apixaban (vs VKA) being associated with a lower risk of myocardial infarction with prior OAC use (180 days: 2.0% vs 3.7% (aHR 0.56, 95% CI 0.33 to 0.91(). CONCLUSIONS: In AUGUSTUS, prior OAC use was associated with fewer ischaemic events but not more bleeding. In patients with AF and ACS and/or undergoing PCI, clinicians can be assured that the trial results can be applied to patients regardless of their prior OAC status. TRIAL REGISTRATION NUMBER: NCT02415400.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Open Heart

DOI

ISSN

2053-3624

Publication Date

February 2022

Volume

9

Issue

1

Location

England

Related Subject Headings

  • Vitamin K
  • Pyridones
  • Pyrazoles
  • Preoperative Period
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Outcome and Process Assessment, Health Care
  • Middle Aged
  • Medication Therapy Management
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Welsh, R. C., Dehghani, P., Lopes, R., Wojdyla, D. M., Aronson, R., Granger, C. B., … Goodman, S. (2022). Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart, 9(1). https://doi.org/10.1136/openhrt-2021-001892
Welsh, Robert C., Payam Dehghani, Renato Lopes, Daniel M. Wojdyla, Ronald Aronson, Christopher B. Granger, Stephan Windecker, et al. “Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.Open Heart 9, no. 1 (February 2022). https://doi.org/10.1136/openhrt-2021-001892.
Welsh RC, Dehghani P, Lopes R, Wojdyla DM, Aronson R, Granger CB, et al. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart. 2022 Feb;9(1).
Welsh, Robert C., et al. “Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.Open Heart, vol. 9, no. 1, Feb. 2022. Pubmed, doi:10.1136/openhrt-2021-001892.
Welsh RC, Dehghani P, Lopes R, Wojdyla DM, Aronson R, Granger CB, Windecker S, Vora AN, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander JH, Goodman S. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart. 2022 Feb;9(1).

Published In

Open Heart

DOI

ISSN

2053-3624

Publication Date

February 2022

Volume

9

Issue

1

Location

England

Related Subject Headings

  • Vitamin K
  • Pyridones
  • Pyrazoles
  • Preoperative Period
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Outcome and Process Assessment, Health Care
  • Middle Aged
  • Medication Therapy Management
  • Male